NASDAQ:NATR

Nature's Sunshine Products Competitors

$20.23
-0.08 (-0.39 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.87
Now: $20.23
$20.35
50-Day Range
$16.48
MA: $18.91
$20.47
52-Week Range
$7.56
Now: $20.23
$21.36
Volume83,785 shs
Average Volume79,114 shs
Market Capitalization$400.47 million
P/E Ratio24.37
Dividend YieldN/A
Beta0.95

Competitors

Nature's Sunshine Products (NASDAQ:NATR) Vs. HRMY, GBIO, AUPH, QURE, TVTX, and IMGN

Should you be buying NATR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Nature's Sunshine Products, including Harmony Biosciences (HRMY), Generation Bio (GBIO), Aurinia Pharmaceuticals (AUPH), uniQure (QURE), Travere Therapeutics (TVTX), and ImmunoGen (IMGN).

Nature's Sunshine Products (NASDAQ:NATR) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

78.3% of Nature's Sunshine Products shares are held by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are held by institutional investors. 16.0% of Nature's Sunshine Products shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Nature's Sunshine Products and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nature's Sunshine Products4.39%11.61%7.14%
Harmony BiosciencesN/AN/AN/A

Earnings & Valuation

This table compares Nature's Sunshine Products and Harmony Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nature's Sunshine Products$362.21 million1.11$6.76 millionN/AN/A
Harmony BiosciencesN/AN/AN/AN/AN/A

Nature's Sunshine Products has higher revenue and earnings than Harmony Biosciences.

Analyst Ratings

This is a summary of current recommendations for Nature's Sunshine Products and Harmony Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nature's Sunshine Products0000N/A
Harmony Biosciences00303.00

Harmony Biosciences has a consensus target price of $51.6667, suggesting a potential upside of 83.54%. Given Harmony Biosciences' higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Nature's Sunshine Products.

Summary

Nature's Sunshine Products beats Harmony Biosciences on 6 of the 8 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

63.3% of Generation Bio shares are owned by institutional investors. Comparatively, 78.3% of Nature's Sunshine Products shares are owned by institutional investors. 16.0% of Nature's Sunshine Products shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Generation Bio and Nature's Sunshine Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Generation BioN/AN/AN/A
Nature's Sunshine Products4.39%11.61%7.14%

Earnings and Valuation

This table compares Generation Bio and Nature's Sunshine Products' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation BioN/AN/AN/AN/AN/A
Nature's Sunshine Products$362.21 million1.11$6.76 millionN/AN/A

Nature's Sunshine Products has higher revenue and earnings than Generation Bio.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Generation Bio and Nature's Sunshine Products, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Generation Bio00603.00
Nature's Sunshine Products0000N/A

Generation Bio currently has a consensus price target of $40.60, suggesting a potential upside of 43.46%. Given Generation Bio's higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Nature's Sunshine Products.

Summary

Nature's Sunshine Products beats Generation Bio on 6 of the 8 factors compared between the two stocks.

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Aurinia Pharmaceuticals and Nature's Sunshine Products' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurinia Pharmaceuticals$320,000.004,918.81$-123,850,000.00($0.89)-13.88
Nature's Sunshine Products$362.21 million1.11$6.76 millionN/AN/A

Nature's Sunshine Products has higher revenue and earnings than Aurinia Pharmaceuticals.

Profitability

This table compares Aurinia Pharmaceuticals and Nature's Sunshine Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%
Nature's Sunshine Products4.39%11.61%7.14%

Institutional and Insider Ownership

51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.3% of Nature's Sunshine Products shares are owned by institutional investors. 16.0% of Nature's Sunshine Products shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Aurinia Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Nature's Sunshine Products has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Aurinia Pharmaceuticals and Nature's Sunshine Products, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurinia Pharmaceuticals01702.88
Nature's Sunshine Products0000N/A

Aurinia Pharmaceuticals currently has a consensus price target of $28.50, suggesting a potential upside of 130.77%. Given Aurinia Pharmaceuticals' higher probable upside, equities analysts plainly believe Aurinia Pharmaceuticals is more favorable than Nature's Sunshine Products.

Summary

Nature's Sunshine Products beats Aurinia Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Nature's Sunshine Products (NASDAQ:NATR) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Earnings & Valuation

This table compares Nature's Sunshine Products and uniQure's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nature's Sunshine Products$362.21 million1.11$6.76 millionN/AN/A
uniQure$7.28 million210.57$-124,200,000.00($3.11)-10.95

Nature's Sunshine Products has higher revenue and earnings than uniQure.

Profitability

This table compares Nature's Sunshine Products and uniQure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nature's Sunshine Products4.39%11.61%7.14%
uniQure-2,738.33%-59.64%-41.47%

Institutional and Insider Ownership

78.3% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 78.3% of uniQure shares are owned by institutional investors. 16.0% of Nature's Sunshine Products shares are owned by company insiders. Comparatively, 2.8% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Nature's Sunshine Products has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Nature's Sunshine Products and uniQure, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nature's Sunshine Products0000N/A
uniQure011113.00

uniQure has a consensus target price of $68.4615, suggesting a potential upside of 100.94%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than Nature's Sunshine Products.

Summary

Nature's Sunshine Products beats uniQure on 7 of the 13 factors compared between the two stocks.

Nature's Sunshine Products (NASDAQ:NATR) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Earnings & Valuation

This table compares Nature's Sunshine Products and Travere Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nature's Sunshine Products$362.21 million1.11$6.76 millionN/AN/A
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21

Nature's Sunshine Products has higher revenue and earnings than Travere Therapeutics.

Profitability

This table compares Nature's Sunshine Products and Travere Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nature's Sunshine Products4.39%11.61%7.14%
Travere Therapeutics-40.24%-29.27%-12.25%

Institutional and Insider Ownership

78.3% of Nature's Sunshine Products shares are owned by institutional investors. 16.0% of Nature's Sunshine Products shares are owned by company insiders. Comparatively, 4.6% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Nature's Sunshine Products has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Nature's Sunshine Products and Travere Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nature's Sunshine Products0000N/A
Travere Therapeutics00503.00

Travere Therapeutics has a consensus target price of $44.3333, suggesting a potential upside of 77.69%. Given Travere Therapeutics' higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than Nature's Sunshine Products.

Summary

Nature's Sunshine Products beats Travere Therapeutics on 9 of the 12 factors compared between the two stocks.

Nature's Sunshine Products (NASDAQ:NATR) and ImmunoGen (NASDAQ:IMGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Earnings & Valuation

This table compares Nature's Sunshine Products and ImmunoGen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nature's Sunshine Products$362.21 million1.11$6.76 millionN/AN/A
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74

Nature's Sunshine Products has higher revenue and earnings than ImmunoGen.

Profitability

This table compares Nature's Sunshine Products and ImmunoGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nature's Sunshine Products4.39%11.61%7.14%
ImmunoGen-77.65%N/A-26.98%

Institutional and Insider Ownership

78.3% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 73.0% of ImmunoGen shares are owned by institutional investors. 16.0% of Nature's Sunshine Products shares are owned by company insiders. Comparatively, 3.8% of ImmunoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Nature's Sunshine Products has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Nature's Sunshine Products and ImmunoGen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nature's Sunshine Products0000N/A
ImmunoGen03402.57

ImmunoGen has a consensus target price of $10.10, suggesting a potential upside of 34.31%. Given ImmunoGen's higher probable upside, analysts clearly believe ImmunoGen is more favorable than Nature's Sunshine Products.

Summary

Nature's Sunshine Products beats ImmunoGen on 8 of the 12 factors compared between the two stocks.


Nature's Sunshine Products Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34-1.0%$950.61 millionN/A-12.60
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.